

Goertek (002241 CH)

Riding on TWS/VR boom; Upgrade to BUY

We upgrade Goertek to BUY (from Hold) as we turn more positive on its product pipeline of AirPods Pro/Studio and Oculus Quest/PSVR in FY20/21E, backed by TWS/wearables upcycle, capacity expansion and impressive yield improvement. We expect 2H20E/FY21E net profit to grow 118%/ 51% YoY, and our FY21/22E EPS are 19%/13% above consensus. Our new TP of RMB46 is based on 40x FY21E P/E, in-line with 1-sd above 5-yr average P/E, given 35% FY20-22E EPS CAGR, strong earnings visibility and improving ROE. Near-term catalysts include product launches of AirPods Studio, HomePod 2 and Oculus Quest2 in 2H20E.

- TWS: AirPods momentum, share gains and improving margin.** We are positive on Goertek's leading market position and growth outlook of its AirPods/TWS segment. We estimate AirPods shipment will grow 45%/22% YoY to 94mn/115mn in FY20E/21E, and Goertek will gain share allocation from 20% in FY19 to 23%/37% in FY20/21E. In addition, we expect improving product mix and production yield to drive earnings upside in after new production lines of AirPods Pro commerce operations in 3Q20E.
- VR/AR: Oculus Quest and Sony PSVR to boost growth.** Goertek is global pioneer in VR/AR industry since partnership with Oculus and Sony in 2014. We expect Goertek to start shipment of Oculus Quest series in 2H20E, and VR/AR segment will regain traction with 82%/40% YoY growth in FY20/21E, backed by new product cycle from Oculus Quest 2 and Sony PSVR 2. In addition, Goertek recently announced to raise RMB4bn convertible bond to expand capacity for 28.6mn TWS earphones, 3.5mn VR/AR products and 5mn AR/VR optical modules, which will help boost share gain and drive revenue growth in FY20-21E.
- Upgrade to BUY with new TP of RMB46.** We revised up our FY20-22E EPS by 27-51%, mainly to reflect our more positive view on AirPods shipment/margin upside given strong consumer demand and cancellation of in-box earphones in iPhone 12 in 2H20E. Our FY21/22E EPS are 19%/13% above consensus, and our TP of RMB46 is based on 40x FY21E P/E, in-line 1-sd above its 5-yr average P/E, given 35% FY20-22E EPS CAGR, strong earnings visibility and improving ROE. Near-term catalysts include product launches of AirPod Studio, HomePod 2 and Oculus Quest2 in 2H20E.

Earnings Summary

(YE31Dec)	FY18	FY19	FY20E	FY21E	FY22E
Revenue (RMB mn)	23,751	35,148	50,443	76,661	93,097
YoY growth (%)	(7.0)	48.0	43.5	52.0	21.4
Net income (RMB mn)	868	1,281	2,454	3,731	4,466
EPS (RMB)	0.27	0.39	0.76	1.15	1.38
YoY growth (%)	(60.3)	46.2	91.7	52.0	19.7
Consensus EPS (RMB)	NA	NA	0.71	0.96	1.2
P/E (x)	144.0	98.5	51.4	33.8	28.3
P/B (x)	8.3	7.8	7.0	6.1	5.2
Yield (%)	0.3	0.3	0.5	0.7	0.9
ROE (%)	6	7.9	13.7	18.0	18.5
Net gearing (%)	37	19	25	39	25

Source: Company data, Bloomberg, CMBIS estimate

BUY (Up)

Target Price **RMB46.0**
 (Previous TP **RMB9.0**)
 Up/Downside **+18.0%**
 Current Price **RMB38.88**

China Technology Sector

Alex Ng

(852) 3900 0881

alexng@cmbi.com.hk

Stock Data

Mkt. Cap. (RMB mn)	126,170
Avg. 3mths t/o (RMB mn)	3,680.44
52W High/Low (RMB)	45.17/14.08
Total Issued Shares (mn)	3,245

Source: Bloomberg

Shareholding Structure

Weifang Geer Group	17.99%
Jiang Bin	11.51%
Jiang Long	6.02%


Source: Bloomberg

Share Performance

	Absolute	Relative
1-mth	0.8%	1.1%
3-mth	66.6%	42.7%
6-mth	75.9%	55.1%

Source: Bloomberg

12-mth Price Performance



Source: Bloomberg

Auditor: Ruihua

Earnings Revision

Figure 1: Earnings revisions

RMB mn	New			Old			Diff (%)		
	FY20E	FY21E	FY22E	FY20E	FY21E	FY22E	FY20E	FY21E	FY22E
Revenue	50,443	76,661	93,097	44,819	60,283	72,241	13%	27%	29%
Gross Profit	8,722	12,978	15,645	7,317	9,725	10,688	19%	33%	46%
Operating Profit	2,877	4,361	5,216	2,304	3,028	3,602	25%	44%	45%
Net profit	2,454	3,731	4,466	1,947	2,555	2,953	26%	46%	51%
EPS (RMB)	0.76	1.15	1.38	0.60	0.78	0.91	27%	47%	51%
Gross Margin	17.3%	16.9%	16.8%	16.3%	16.1%	14.8%	1ppt	0.8ppt	2ppt
Operating Margin	5.7%	5.7%	5.6%	5.1%	5.0%	5.0%	0.6ppt	0.7ppt	0.6ppt
Net Margin	4.9%	4.9%	4.8%	4.3%	4.2%	4.1%	0.5ppt	0.6ppt	0.7ppt

Source: Bloomberg, CMBIS

Figure 2: CMBIS estimates vs consensus


RMB mn	CMBIS			Consensus			Diff (%)		
	FY20E	FY21E	FY22E	FY20E	FY21E	FY22E	FY20E	FY21E	FY22E
Revenue	50,443	76,661	93,097	48,879	68,260	82,327	3%	12%	13%
Gross Profit	8,722	12,978	15,645	8,084	11,311	13,684	8%	15%	14%
Operating Profit	2,877	4,361	5,216	2,810	4,005	5,055	2%	9%	3%
Net profit	2,454	3,731	4,466	2,328	3,344	4,205	5%	12%	6%
EPS (RMB)	0.76	1.15	1.38	0.71	0.96	1.21	6%	20%	13%
Gross Margin	17.3%	16.9%	16.8%	16.5%	16.6%	16.6%	0.8ppt	0.4ppt	0.2ppt
Operating Margin	5.7%	5.7%	5.6%	5.7%	5.9%	6.1%	0ppt	-0.2ppt	-0.5ppt
Net Margin	4.9%	4.9%	4.8%	4.8%	4.9%	5.1%	0.1ppt	0ppt	-0.3ppt

Source: Bloomberg, CMBIS

Financial Analysis


Expect revenue/net profit to grow at 36%/35% CAGR during FY20-22E

Figure 3: Revenue growth estimates



Source: Company data, CMBIS estimates

Figure 4: Revenue breakdown (FY17-22E)



Source: CMBIS estimates

Figure 5: Revenue breakdown

RMB mn	FY18	FY19	FY20E	FY21E	FY22E
Precision component	9,931	10,620	12,171	13,758	15,401
...YoY	-4%	7%	15%	13%	12%
Speaker/Receiver	6,500	6,175	6,793	7,336	7,703
MIC (ECM/MEMS)	2,200	2,860	3,289	3,782	4,350
MEMS sensor	300	330	380	417	459
Antenna	300	390	585	761	989
Optical component module	631	865	1,125	1,462	1,901
Hearable products	6,813	14,823	24,027	44,308	54,043
...YoY	25%	118%	62%	84%	22%
AirPods	2,240	9,347	16,365	33,862	41,470
Android TWS	1,000	1,400	3,000	5,040	6,250
Smart Speakers	500	850	1,275	1,849	2,588
Other smart products	6,627	8,514	12,935	17,153	22,067
...YoY	-29%	28%	52%	33%	29%
Smart Watch	2,000	3,000	4,500	6,075	8,201
VR/AR	3,000	3,300	6,000	8,400	10,920
Robotics/UAV/smart light	1,627	2,214	2,435	2,678	2,946
Non-main business	380	1,191	1,310	1,441	1,586
...YoY	-13%	214%	10%	10%	10%
Total	23,751	35,148	50,443	76,661	93,097
...YoY	-7%	48%	44%	52%	21%

Source: Company data, CMBIS

Figure 6: P&L forecast

RMB mn	FY18	FY19	1Q20	2Q20	3Q20E	4Q20E	FY20E	FY21E	FY22E
Revenue	23,751	35,148	6,474	9,099	15,121	19,749	50,443	76,661	93,097
...YoY	-7%	48%	13%	16%	43%	79%	44%	52%	21%
Cost of sales	(19,282)	(29,726)	(5,294)	(7,470)	(12,524)	(16,434)	(41,722)	(63,682)	(77,453)
Gross profit	4,469	5,422	1,180	1,629	2,597	3,316	8,722	12,978	15,645
GPM (%)	18.8%	15.4%	18.2%	17.9%	17.2%	13.9%	17.3%	16.9%	16.8%
...YoY	-20%	21%	23%	41%	46%	117%	61%	49%	21%
SG&A	(1,609)	304	(352)	(288)	(613)	(916)	(2,169)	(3,296)	(4,003)
...% of rev	6.8%	0.9%	5.4%	3.2%	4.1%	4.6%	4.3%	4.3%	4.3%
R&D	(1,334)	(1,807)	(338)	(635)	(650)	(1,152)	(2,774)	(4,140)	(5,027)
...% of rev	5.6%	5.1%	5.2%	7.0%	4.3%	5.8%	5.5%	5.4%	5.4%
Operating profit	1,006	1,496	360	618	1,096	780	2,877	4,361	5,216
OPM (%)	4.2%	4.3%	5.6%	6.8%	7.2%	3.9%	5.7%	5.7%	5.6%
...YoY	-60%	49%	46%	53%	100%	162%	92%	52%	20%
Net profit	868	1,281	294	487	932	719	2,454	3,731	4,466
NPM (%)	3.7%	3.6%	4.5%	5.3%	6.2%	3.6%	4.9%	4.9%	4.8%
...YoY	-59%	48%	45%	52%	102%	143%	92%	52%	20%

Source: Company data, CMBIS

Valuation

Upgrade to BUY with new TP of RMB46.0


We revised up FY20-22E EPS by 27-51% to reflect our positive view on AirPods shipment/margin upside given strong consumer demand and cancellation of in-box earphones in iPhone12 in 2H20E. Our FY21/22E EPS are 19%/13% above consensus. Our TP of RMB46 is based on 40x FY21E P/E, in-line 1-sd above its 5-yr average P/E, given 35% FY20-22E EPS CAGR, strong earnings visibility and improving ROE. Near-term catalysts include product launches of AirPods Studio, HomePod 2 and Oculus Quest2 in 2H20E.

Figure 7: Peers' valuation

Company	Ticker	Rating	Market Cap US\$(mn)	Price (LC)	TP (LC)	Up/Down -side	P/E (x)		P/B (x)		ROE (%)	
							FY20E	FY21E	FY20E	FY21E	FY20E	FY21E
A-listed components												
Goertek	002241 CH	Buy	18,428	38.88	46.0	18%	51.2	33.8	7.0	6.1	13.7	18.0
Luxshare	002475 CH	Buy	52,684	51.65	74.2	44%	38.8	29.2	9.8	7.5	25.2	25.8
O-film	002456 CH	NR	5,770	14.66	NA	NA	29.1	21.4	3.6	3.1	12.3	14.5
Sunway	300136 CH	NR	7,946	56.50	NA	NA	38.9	28.1	8.9	6.8	23.6	24.5
BOE	000725 CH	NR	26,583	5.30	NA	NA	44.2	22.2	1.9	1.8	4.1	7.2
Hans Laser	002008 CH	NR	5,307	34.05	NA	NA	29.7	23.0	3.8	3.3	12.5	14.6
Lens Tech	300433 CH	NR	20,815	32.51	NA	NA	33.3	26.6	5.2	4.5	17.0	18.0
Everwin	300115 CH	NR	3,002	22.59	NA	NA	38.5	27.3	4.2	3.8	11.1	13.5
Holitech	002217 CH	NR	2,517	5.53	NA	NA	-	-	-	-	-	-
Average							38.0	26.4	5.6	4.6	14.9	17.0
H-listed components												
FIT Hon Teng	6088 HK	Buy	2,603	2.93	4.1	40%	15.5	10.7	1.1	1.0	7.3	9.8
AAC Tech	2018 HK	Hold	7,375	47.30	47.3	0%	23.8	17.0	2.5	2.4	10.7	13.9
Sunny Optical	2382 HK	Buy	16,615	117.40	148.0	26%	25.4	19.5	6.9	5.3	27.2	27.2
Tongda	698 HK	Hold	355	0.43	0.5	18%	15.2	6.1	0.4	0.4	2.8	6.9
BYDE	285 HK	Buy	10,844	37.30	37.7	1%	13.2	12.8	3.5	2.9	26.5	22.4
Q tech	1478 HK	Buy	1,385	9.16	16.6	81%	12.1	10.0	2.7	2.2	22.0	21.8
TK Group	2283 HK	Buy	280	2.60	2.3	-10%	4.7	4.0	1.7	1.7	35.7	41.7
Truly	732 HK	NR	390	0.92	NA	NA	-	-	-	-	-	-
SMIC	981 HK	NR	29,002	18.42	NA	NA	52.8	56.6	1.3	1.3	3.2	2.1
YOFC	6869 HK	NR	2,452	13.34	NA	NA	11.8	9.8	0.9	0.9	8.4	9.2
O-NET	877 HK	NR	683	6.35	NA	NA	24.0	18.7	2.1	1.9	7.1	9.1
Cowell	1415 HK	NR	306	2.85	NA	NA	6.2	5.2	0.9	0.9	11.2	13.8
Average							18.6	15.5	2.2	1.9	14.7	16.2


Source: Bloomberg, CMBIS

Figure 8: 12M forward P/E band



Source: Company data, CMBIS

Figure 9: 12M forward P/B band



Source: Company data, CMBIS

Financial Summary

Income statement

YE 31 Dec (RMB mn)	FY18A	FY19A	FY20E	FY21E	FY22E
Revenue	23,751	35,148	50,443	76,661	93,097
Cost of sales	19,282	29,726	41,722	63,682	77,453
Gross profit	4,469	5,422	8,722	12,978	15,645
Selling exp	569	534	908	1,380	1,676
Admin exp (excl. R&D)	1,040	838	1,261	1,917	2,327
R&D exp	1,334	1,807	2,774	4,140	5,027
Finance costs	318	364	421	533	646
Other operating exp.	201	383	480	648	753
Operating profit	1,006	1,496	2,877	4,361	5,216
Other non-oper exp.	(13)	(25)	(25)	(25)	(25)
Pre-tax profit	993	1,472	2,852	4,336	5,191
Income tax expense	149	192	399	607	727
Minority interests	(23)	(1)	(1)	(1)	(1)
Net profit to shareholders	868	1,281	2,454	3,731	4,466

Cash flow summary

YE 31 Dec (RMB mn)	FY18A	FY19A	FY20E	FY21E	FY22E
Net profit	844	1,279	2,453	3,729	4,464
Depreciation/amortization	1,635	1,992	1,319	1,512	1,682
Change in working capital	(866)	1,542	(1,143)	(3,802)	(109)
Others	663	638	421	533	646
Net cash from operating	2,276	5,451	3,049	1,972	6,683
Capex	4,240	3,177	3,000	3,000	3,000
Other	(8,503)	(6,215)	(6,000)	(6,000)	(6,000)
Net cash from investing	(4,263)	(3,038)	(3,000)	(3,000)	(3,000)
Share issuance	16	1	0	0	0
Dividend paid	522	595	608	924	1,106
Other	92	(1,933)	363	(381)	(858)
Net cash from financing	630	(1,337)	971	543	248
Net change in cash	(1,356)	1,077	1,020	(485)	3,931
Cash at beginning of the year	3,358	2,008	3,095	4,115	3,630
Exchange difference	6	10	0	0	0
Cash at the end of the year	2,008	3,095	4,115	3,630	7,562

Balance sheet

YE 31 Dec (RMB mn)	FY18A	FY19A	FY20E	FY21E	FY22E
Current assets	13,820	17,704	23,373	34,480	37,813
Cash & equivalents	2,392	3,613	4,633	4,148	8,080
Account receivables	7,211	8,147	10,974	17,504	17,062
Inventories	3,549	5,296	7,118	12,180	12,024
Prepayment	161	218	218	218	218
Other current assets	508	429	429	429	429
Non-current assets	15,922	16,957	18,638	20,126	21,444
PPE	11,117	11,502	13,184	14,672	15,990
Deferred income tax	205	198	198	198	198
Other non-current assets	4,600	5,256	5,256	5,256	5,256
Total assets	29,742	34,660	42,011	54,607	59,258
Current liabilities	13,453	17,558	23,063	32,853	34,146
Deferred income	104	105	105	105	105
Account payables	5,615	9,675	13,180	20,970	20,263
Tax payable	91	140	140	140	140
Other current liabilities	7,642	7,639	9,639	11,639	13,639
Non-current liabilities	1,100	973	973	973	973
Deferred income	284	397	397	397	397
Deferred tax liability	209	233	233	233	233
Other non-current liabilities	606	344	344	344	344
Total liabilities	14,553	18,531	24,036	33,827	35,119
Share capital	3,245	3,245	3,245	3,245	3,245
Reserves	11,956	12,862	14,709	17,515	20,875
Minority interest	(12)	22	21	19	18
Shareholders' equity	15,190	16,129	17,974	20,780	24,138
Total equity and liabilities	29,742	34,660	42,011	54,607	59,258

Key ratios

YE 31 Dec	FY18A	FY19A	FY20E	FY21E	FY22E
Sales mix (%)					
Precision Components	42	30	24	18	17
Hearable products	29	42	48	58	58
Other smart products	28	24	26	22	24
Non-main business	2	3	3	2	2
Growth (%)					
Revenue	(7.0)	48.0	43.5	52.0	21.4
Gross profit	(20.5)	21.3	60.9	48.8	20.5
Operating profit	(59.7)	48.7	92.3	51.6	19.6
Net profit	(59.4)	47.6	91.7	52.0	19.7
Profit & loss ratio (%)					
Gross margin	18.8	15.4	17.3	16.9	16.8
Operating margin	4.2	4.3	5.7	5.7	5.6
Net profit margin	3.7	3.6	4.9	4.9	4.8
Balance sheet ratio					
Net debt/total equity (x)	0.4	0.2	0.3	0.4	0.2
Current ratio (x)	1.0	1.0	1.0	1.0	1.1
Receivable turnover days	104	80	80	80	80
Inventory turnover days	62	54	54	54	54
Payable turnover days	100	94	94	94	94
Profitability (%)					
ROE	5.7	7.9	13.7	18.0	18.5
ROA	2.9	3.7	5.8	6.8	7.5
Per share data (RMB)					
EPS	0.27	0.39	0.76	1.15	1.38
DPS	0.10	0.10	0.19	0.28	0.34

Source: Company data, CMBIS estimates

Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIS Ratings

BUY : Stock with potential return of over 15% over next 12 months
HOLD : Stock with potential return of +15% to -10% over next 12 months
SELL : Stock with potential loss of over 10% over next 12 months
NOT RATED : Stock is not rated by CMBIS

OUTPERFORM : Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM : Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Securities Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Securities Limited ("CMBIS") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIS does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIS recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIS, solely for the purpose of supplying information to the clients of CMBIS and/or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIS nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIS has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIS provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIS may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIS may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIS may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIS does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIS may have a conflict of interest that could affect the objectivity of this report and CMBIS will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIS.

Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.") of the Order, and may not be provided to any other person without the prior written consent of CMBIS.

For recipients of this document in the United States

CMBIS is not a registered broker-dealer in the United States. As a result, CMBIS is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.